JDS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Journal of Dairy Science Vol. 78 No. 5 1062-1067
© 1995 by American Dairy Science Association ®
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hogan, J. S.
Right arrow Articles by Shuster, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hogan, J. S.
Right arrow Articles by Shuster, D.

Efficacy of Recombinant Bovine Interleukin-2 as an Adjunct to Dry Cow Therapy

J. S. Hogan 1, K. L. Smith 1, D. A. Todhunter 1, P. S. Schoenberger 1, and D. Shuster 2

1 Department of Dairy Science, The Ohio State University, Ohio Agricultural Research and Development Center Wooster 44691
2 American Cyanamid Company, Princeton, NJ 08543

Recombinant bovine interleukin-2 was tested as adjunct therapy to intramammary infusion of antibiotics at drying off. Cows were assigned randomly within three commercial herds to either recombinant bovine interleukin-2 or PBS treatment groups at drying off. Ninety-five cows received intramammary infusions of 1 mg of recombinant bovine interleukin-2 in each quarter immediately preceding intramammary infusion of a product for antibiotic therapy of dry cows. Ninety-four cows received intramammary infusion of 10 ml of endotoxin-free PBS in each quarter immediately preceding the antibiotic therapy. Cure rates for IMI present at drying off did not differ between cows treated with recombinant bovine interleukin-2 and those treated with PBS. Intramammary infusion of recombinant bovine interleukin-2 did not affect the rate of new IMI during the dry period. Milk production and SCC during the first 3 mo of lactation subsequent to therapy did not differ between treatment groups. Intramammary infusion of recombinant bovine interleukin-2 was not effective as an adjunct to antibiotic therapy for dry cows.

Key Words: recombinant bovine interleukin-2 • dry cow • antibiotic therapy • mastitis

Submitted on October 20, 1994
Accepted on January 30, 1995




This article has been cited by other articles:


Home page
 J DAIRY SCIHome page
K. Huijps and H. Hogeveen
Stochastic Modeling to Determine the Economic Effects of Blanket, Selective, and No Dry Cow Therapy
J Dairy Sci, March 1, 2007; 90(3): 1225 - 1234.
[Abstract] [Full Text] [PDF]

Home page
 J DAIRY SCIHome page
R. T. Dingwell, K. E. Leslie, T. F. Duffield, Y. H. Schukken, L. DesCoteaux, G. P. Keefe, D. F. Kelton, K. D. Lissemore, W. Shewfelt, P. Dick, et al.
Efficacy of Intramammary Tilmicosin and Risk Factors for Cure of Staphylococcus aureus Infection in the Dry Period
J Dairy Sci, January 1, 2003; 86(1): 159 - 168.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by the American Dairy Science Association ®.